AngioDynamics (NASDAQ:ANGO) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS

AngioDynamics (NASDAQ:ANGO) issued its quarterly earnings data on Tuesday. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04, FiscalAI reports. The business had revenue of $86.61 million for the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics updated its FY 2027 guidance to -0.290–0.240 EPS.

Here are the key takeaways from AngioDynamics’ conference call:

• AngioDynamics delivered a solid FY2026, with revenue up 9.4% to $320.2 million and MedTech revenue up 18.4%, showing continued mix shift toward higher-growth businesses.
• Auryon remained a standout, posting its 20th consecutive quarter of double-digit growth and benefiting from share gains across hospital and office-based lab settings, plus international adoption.
• NanoKnife posted exceptional momentum, with full-year revenue up 35.2% and a record fourth quarter driven by prostate procedures, supported by better clinical data and improving reimbursement coverage.
• Management said mechanical thrombectomy remains a key growth engine, but near-term results were uneven; AlphaVac grew strongly while AngioVac declined in the quarter, and the company is making commercial changes to improve execution.
• Profitability and cash generation improved despite tariffs, with FY2026 adjusted EBITDA rising to $13.2 million, gross margin at 54.6%, and the company ending the year with $53.9 million in cash and no debt. Management guided FY2027 revenue to $336 million-$341 million and expects MedTech growth of 12%-15%.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $14.47 on Thursday. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $14.80. The business has a fifty day moving average price of $12.14 and a 200-day moving average price of $11.33. The company has a market capitalization of $597.89 million, a PE ratio of -16.63 and a beta of 0.34.

Trending Headlines about AngioDynamics

Here are the key news stories impacting AngioDynamics this week:

• Positive Sentiment: AngioDynamics reported Q4 revenue of $86.61 million, beating estimates, and EPS of $(0.07), which was better than expected. The company also said gross margin expanded and Med Tech sales surged. AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands
• Positive Sentiment: The company raised FY 2027 sales guidance to $336 million-$341 million, above consensus, signaling confidence in continued growth. AngioDynamics earnings report and transcript
• Positive Sentiment: HC Wainwright raised its price target on AngioDynamics to $19 from $16 and kept a Buy rating, reinforcing a bullish view on the stock. HC Wainwright raises price target on AngioDynamics
• Positive Sentiment: Another HC Wainwright update also lifted Q4 2027 EPS expectations, even after trimming the estimate, suggesting analysts still see upside versus the current share price. AngioDynamics stock page
• Neutral Sentiment: The company remains unprofitable, with a negative net margin and return on equity, so investors are still watching for a sustained path to earnings improvement.

Analysts Set New Price Targets

ANGO has been the subject of several research analyst reports. Freedom Capital upgraded shares of AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. HC Wainwright increased their target price on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday. Zacks Research cut AngioDynamics from a “strong-buy” rating to a “hold” rating in a research note on Monday, March 30th. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a report on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.50.

Institutional Trading of AngioDynamics

A number of institutional investors and hedge funds have recently bought and sold shares of ANGO. Franklin Resources Inc. lifted its holdings in shares of AngioDynamics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after purchasing an additional 1,076 shares in the last quarter. Deutsche Bank AG raised its position in AngioDynamics by 5.9% in the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after buying an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in AngioDynamics during the 4th quarter valued at about $27,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of AngioDynamics by 5.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock valued at $569,000 after acquiring an additional 2,263 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock worth $608,000 after acquiring an additional 2,510 shares during the period. 89.43% of the stock is currently owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.